Compare ULH & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULH | SRZN |
|---|---|---|
| Founded | 1932 | 2015 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Trucking Freight/Courier Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.9M | 304.3M |
| IPO Year | 2004 | N/A |
| Metric | ULH | SRZN |
|---|---|---|
| Price | $17.21 | $21.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $20.00 | ★ $38.00 |
| AVG Volume (30 Days) | 61.4K | ★ 71.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,461,708,000.00 | N/A |
| Revenue This Year | $2.73 | $75.35 |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.73 | $8.00 |
| 52 Week High | $30.76 | $35.00 |
| Indicator | ULH | SRZN |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 31.41 |
| Support Level | $14.82 | $20.02 |
| Resistance Level | $18.79 | $24.50 |
| Average True Range (ATR) | 0.96 | 1.99 |
| MACD | 0.57 | -0.46 |
| Stochastic Oscillator | 85.44 | 1.25 |
Universal Logistics Holdings Inc is an asset-light provider of customized transportation and logistics solutions throughout the United States, and in Mexico, Canada, and Colombia. It offers services such as truckload, brokerage, intermodal, dedicated, and value-added services. The firm has three reportable segments, namely contract logistics, intermodal, and trucking. The company generates the key revenue from Contract Logistics, which provides value-added and dedicated transportation services to support inbound and internal logistics requirements of industrial manufacturers and retailers, generally under contractual arrangements of one year or longer. Geographically, the firm generates the majority of its revenue from the United States, followed by Mexico, Canada, and Colombia.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).